The system is used to treat individuals with knee osteoarthritis who were not able to receive relief from non-surgical or surgical treatments, according to an April 10 news release.
The implantable shock absorber allows patients who are not good candidates for joint replacement surgery another option to treat osteoarthritis.
With the authorization, Moximed is able to bring the system and procedure to patients in the U.S., the release said.
David Flanigan, MD, professor of orthopedics at the Ohio State University College of Medicine in Columbus, conducted a clinical trial of the device in September with a success rate of 86 percent.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
